FindTrial
Sign In

Ibrutinib for mantle cell lymphoma: multicenter retrospective analysis

Ibrutinib for relapsed or refractory mantle cell lymphoma: multicenter retrospective analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0004207
Enrollment
100
Registered
2019-08-19
Start date
2019-09-01
Completion date
Unknown
Last updated
2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Samsung Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Patients with MCL diagnosed by a pathologist (based on the WHO 2017 classification) 1) mantle cell lymphoma 2) leukemic nonnodal mantle cell lymphoma 3) in situ mantle cell neoplasia - Aged = 19 years - Relapsed or refractory patients treated with ibrutinib, including relapse after autologous stem cell transplantation

Exclusion criteria

Exclusion criteria: Patients whose clinical and pathological data are not available Patients who were not treated with ibrutinib

Design outcomes

Primary

MeasureTime frame
Progression free survival—

Secondary

MeasureTime frame
Overall survival—

Countries

Korea, Republic of

Contacts

Public ContactWon Seog Kim

Samsung Medical Center

info@cisl.co.kr+82-2-3410-3459

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026